MRSI data (baseline removed from LCModel) from three patients with grade IV, II and IV gliomas, who were prior to any treatment (a), recurrent within 10 months (b) and over 3 years (c), respectively. The metabolite maps were quantified using LCModel and plotted with the range between 0 and 0.36 for tCho/NAA and between 0 and 6 for mI/tCho. Higher tCho/NAA in the recent active tumor lesions, while mI/tCho was elevated in the region that had been diagnosed stable for a long period.